NCT03501979: Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

NCT03501979
Breast Cancer Type: HER2+
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Patients must have evidence of leptomeningeal disease (LMD) 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03501979

Comments are closed.

Up ↑